Healthcare Private Placement and M&A Transactions Review Week Ending June 23, 2024

iOnctura: The company raised EUR 80 million of Series B venture funding in a deal led by Syncona on June 20, 2024. M Ventures, Schroders Capital, 3B Future Health Fund, European Innovation Council Fund, Inkef and VI Partners also participated in the round. The company is a developer of next-generation bio-molecules intended for the treatment of cancer and fibrosis.

Elion Therapeutics: The company raised $81 million of Series B venture funding in a deal led by Deerfield Management and AMR Action Fund on June 17, 2024, putting the company’s pre-money valuation at $82 million. Illinois Ventures and other undisclosed investors also participated in the round. The company is a provider of clinical research and development services intended to treat systemic and life-threatening fungal infections.

Evecxia Therapeutics: The company is in the process of raising $55 million of Series C venture funding on June 17, 2024. The company is an operator of a biotechnology business dedicated to realizing the therapeutic potential of amplifying serotonin synthesis for neuropsychiatric conditions.

Yellowstone Biosciences: The company raised EUR 16.5 million of Series A venture funding in a deal led by Syncona on June 20, 2024. The company is a developer of a therapeutic biotechnology platform designed to create highly selective targeted therapies for cancer.

Peerbridge Health: The company raised $13.7 million in Series B venture funding from undisclosed investors on June 18, 2024, putting the company’s pre-money valuation at $18.3 million. The company is a manufacturer of a wearable device for electrocardiogram monitoring.

Rapafusyn Pharmaceuticals: The company raised $28 million of Series A venture funding in a deal led by 3E Bioventures, Proxima Ventures and Lapam Capital on June 20, 2024. The company is an operator of a pharmaceutical platform intended to discover and develop therapeutic drugs based on non-degrading molecular glues.

Ethris: The company raised EUR 7.6 million of venture funding in the form of convertible debt from Cipla and Bill & Melinda Gates Foundation on June 18, 2024. The company is a developer of stabilized non-immunogenic mRNA platform designed to develop innovative therapies and vaccines.

InNeuroCo: The company raised $8.2 million of venture funding from undisclosed investors on June 21, 2024. The company is a manufacturer of medical technologies for the neurovascular industry.

ElmediX: The company raised EUR 5 million of Series A venture funding from undisclosed investors on June 17, 2024. The company is a developer of disruptive solutions for pancreatic cancer and other metastatic cancers.

INGENIA Therapeutics: The company raised $5 million of venture funding from undisclosed investors on June 21, 2024. The company is a developer of a therapeutic antibody candidate designed for capillary diseases.

FluoretiQ: The company is in the process of raising GBP 3 million of venture funding on June 18, 2024. The company is a developer of a microbial testing technology for early diagnosis and effective treatment of infectious disease.

Myocene: The company raised $3 million of funding in the form of equity and capital loan from Wallonie Entreprendre, Investsud and Noshaq on June 18, 2024. The company is a developer of a sports technology designed to measure muscle fatigue and performance.

Prana Thoracic: The company raised an additional $2.2 million of Series A venture funding from undisclosed investors on June 18, 2024, putting the company’s pre-money valuation at $10.7 million. The company is a manufacturer of medical devices intended to detect and intervene in early-stage lung cancer.

Analytical Biological Services: The company received an undisclosed amount of development capital from 3 Boomerang Capital on June 17, 2024. The company is a provider of cell cultures and QC services for biological research.

Primrose Bio: The company raised an undisclosed amount of venture funding from 1315 Capital on June 17, 2024. The company is a developer of constructive biology technologies designed to accelerate the evolution of highly efficient enzymes and microbes.

ReviR Therapeutics: The company raised an undisclosed amount of venture funding from CMT Research Foundation on June 19, 2024. The company is a developer of RNA therapeutics intended to treat cancer, rare genetic disorders, and infectious diseases.

Silk Road Medical / Boston Scientific: The company reached a definitive agreement to be acquired by Boston Scientific for $1.16 billion on June 18, 2024. Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke.

Proteologix / Johnson & Johnson: The company was acquired by Johnson & Johnson for $850 million on June 21, 2024. The company is an operator of a biotechnology business focused on immunology and inflammation diseases.

Sharecare / Altaris: The company entered into a definitive agreement to be acquired by Altaris Capital Partners through an estimated $518.2 million public-to-private LBO on June 21, 2024. Sharecare Inc is a digital healthcare platform company that helps members consolidate and manage various components of their health in one place.

AVROBIO / Tectonic Therapeutic: The company was acquired by Tectonic Therapeutic through a reverse merger resulting in the combined entity trading on the Nasdaq market under the ticker symbol TECX on June 20, 2024. Avrobio Inc is a clinical-stage company engaged in developing potentially curative ex vivo lentiviral gene therapies

BCI Pharma / Gedeon Richter: The company was acquired by Gedeon Richter for an undisclosed amount on June 19, 2024. The company is an operator of a biotechnology firm focused on small molecule drug discovery.

Lykon / Lifesum: The company was acquired by Lifesum for an undisclosed amount on June 19, 2024. The company is a provider of blood testing services intended to conduct DNA or blood checks to suggest tailored supplements.

Typeless / Doctolib: The company was acquired by Doctolib for an undisclosed amount on June 21, 2024. The company is a developer of a healthcare application intended for medical speech and text comprehension and analysis.

Vapotherm / Multiple Investors: The company entered into a definitive agreement to be acquired by SLR Investment Corp. BDC and Perceptive Advisors through a public-to-private LBO on June 17, 2024 for an undisclosed amount. Vapotherm Inc is a medical technology company engaged in the development and commercialization of its proprietary Hi-VNI technology products.